Brought to you by 
Abgenix, Human Genome Sciences in antibody drug deal
07 Jan 2000
Executive Summary
In a multi-year deal, Human Genome Sciences will apply Abgenix's XenoMouse technology to its own drug targets to develop fully human antibody drug candidates. HGS plans to develop and sell the resulting therapeutics.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Intra-Biotech Deal
- Product or Technology Swap
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Abgenix, Human Genome Sciences in antibody drug deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice